Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical staining for GAPDH was investigated in 137 HCC tissue samples from our center.
|
31239764 |
2019 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Abbreviations:</b> ALDO: aldolase, fructose-bisphosphate; CQ: chloroquine; DLAT/PDCE2: dihydrolipoamide S-acetyltransferase; EMT: epithelial-mesenchymal transition; ENO: enolase; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GLS/GLS1: glutaminase; GLUL/GS: glutamine-ammonia ligase; GPI/PGI: glucose-6-phosphate isomerase; HCC: hepatocellular carcinoma; HGF: hepatocyte growth factor; HK: hexokinase; LDH: lactate dehydrogenase; LIHC: liver hepatocellular carcinoma; LIR: LC3-interacting region; PDH: pyruvate dehydrogenase; PDHA1: pyruvate dehydrogenase E1 alpha 1 subunit; PDHX: pyruvate dehydrogenase complex component X; PFK: phosphofructokinase; PK: pyruvate kinase; RTK: receptor tyrosine kinase; TCGA: The Cancer Genome Atlas.
|
30786811 |
2019 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Results showed that <i>TFG</i> and <i>SFRS4</i> are among the most reliable reference genes, and <i>ACTB</i> ranks third and acts quite well as a classical choice, whereas <i>GAPDH, HPRT1</i> and <i>TUBB</i> are not proper reference genes in qRT-PCR assays among the HCC cell lines.
|
29180379 |
2017 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The differentially expressed genes (DEGs) in HCC samples were screened using the ΔΔCt method with the homogenized internal GAPDH.
|
26045814 |
2015 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The relative Heparanase mRNA expression level (Heparanase: glyceraldehyde-3-phosphate dehydrogenase ratio) in hepatocellular carcinoma was lower than that in noncancerous tissue (P < 0.05).
|
23771368 |
2014 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The involvement of GAPDH in several hepatocarcinogenic mechanisms (e.g. viral hepatitis, metabolic alterations) and its sensitivity to a new class of prospective anticancer agents prompted us to review the current understanding of the therapeutic potential of targeting GAPDH in HCC.
|
22964488 |
2012 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Hepatocellular carcinoma-associated protein markers investigated by MALDI-TOF MS.
|
21472284 |
2012 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
RT-PCR demonstrated that the expression of relative HMGB1 mRNA (HMGB1/GAPDH) was 0.854 ± 0.172; the highest in the tissue of HCC, significantly up-regulated compared with that of 0.527 ± 0.155 in LAT and of 0.405 ± 0.087 in normal liver tissues (P < 0.001).
|
21953322 |
2012 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
HMBS and GAPDH were identified as the optimal reference genes for normalizing gene expression data between paired tumoral and adjacent non-tumoral tissues derived from patients with HCC.
|
19036168 |
2008 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Expression of these 6 genes relative to that of GAPDH was measured by QRT-PCR in 82 HCCs.
|
18202799 |
2008 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Proteomic analysis of autoantibodies in patients with hepatocellular carcinoma.
|
16767786 |
2006 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Quantitative real-time PCR demonstrated that the mean ratio of FGFR3 mRNA to glyceraldehyde-3-phosphate dehydrogenase (GADPH) mRNA in HCC tissue was 0.250, whereas the ratio in non-neoplastic liver tissue was 0.014.
|
16149130 |
2005 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The expression levels of KiSS-1, hOT7T175 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) messenger RNAs (mRNAs) were analyzed quantitatively by real-time reverse transcriptase polymerase chain reaction (RT-PCR) in 60 surgically resected HCCs.
|
12898236 |
2003 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Plasma GAPDH mRNA concentrations in HCC patients were significantly higher than those in healthy individuals, both with or without filtration (P <0.0 5 for filtered plasma samples; P <0.005 for unfiltered plasma samples).
|
12142376 |
2002 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Here we show that transcriptional activity is reduced by deletion of the nucleotides from -181 to -144 (relative to the transcriptional start site) in the promoter of human GAPDH gene, both in CHO (derived from Chinese hamster ovary) and HepG2 (derived from human hepatoma) cells.
|
9378702 |
1997 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Comparison of glyceraldehyde-3-phosphate dehydrogenase and 28s-ribosomal RNA gene expression in human hepatocellular carcinoma.
|
8666326 |
1996 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
When stably transfected and expressed in 3T3-F442A preadipocytes and H35 hepatoma cells, the intact human GAPDH gene is induced 10-fold by insulin in 3T3-F442A adipocytes and 3-fold by insulin in H35 hepatoma lines, which is similar to the induction obtained with the endogenous gene.
|
2839830 |
1988 |
Colorectal Carcinoma
|
0.340 |
Biomarker
|
disease |
BEFREE |
However, given the proliferative drive of malignant cells, many reference genes such as beta-actin (ACTB) and glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) which play critical roles in cell membrane organization and glycolysis, may be dysregulated in tumors versus their corresponding normal controls METHODS: Because Next Generation Sequencing (NGS) technology has several advantages over hybridization-based technologies, such as independent detection and quantitation of transcription levels, greater sensitivity, and increased dynamic range, we evaluated colorectal cancers (CRC) and their histologically normal tissue counterparts by NGS to evaluate the expression of 21 "classical" reference genes used as normalization standards for PCR based methods.
|
31409279 |
2019 |
Colorectal Carcinoma
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, the current study successfully developed the single‑tube duplex RT‑qPCR to simultaneously detect VDR and GAPDH expression in colorectal cancer cells.
|
29067439 |
2017 |
Colorectal Carcinoma
|
0.340 |
Biomarker
|
disease |
CTD_human |
Highly Expressed Genes in Rapidly Proliferating Tumor Cells as New Targets for Colorectal Cancer Treatment.
|
25944804 |
2015 |
Colorectal Carcinoma
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
The concentrations of beta-catenin mRNA, P-selectin mRNA, cytokeratin 20 mRNA, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA in the plasma, the mononuclear and red cells (MARC) from metastatic colorectal (CRC) patients whose blood samples were centrifuged with 2 different forces, were measured.
|
17880935 |
2007 |
Colorectal Carcinoma
|
0.340 |
Biomarker
|
disease |
BEFREE |
TS, DPD and TP mRNA expression was analysed by real-time reverse-transcription polymerase chain reaction in primary CRC and adjacent normal tissues from 53 patients with glyceraldehyde-3-phosphate dehydrogenase as housekeeping gene.
|
17047489 |
2006 |
Squamous cell carcinoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Elevated GAPDH expression is associated with the proliferation and invasion of lung and esophageal squamous cell carcinomas.
|
25944651 |
2015 |
Squamous cell carcinoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
GAPD and tubulin are suitable internal controls for qPCR analysis of oral squamous cell carcinoma cell lines.
|
18621570 |
2009 |
Squamous cell carcinoma
|
0.330 |
Biomarker
|
disease |
CTD_human |
Proteomics of buccal squamous cell carcinoma: the involvement of multiple pathways in tumorigenesis.
|
15274141 |
2004 |